GILD Gilead Sciences Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 24.36 P/E
- 9.32 P/S
- 10.17 P/B
- 4.414 EPS
- 39.33% Cash ROIC
- 0.34 Cash Ratio
- 0.00 / N/A % Dividend
- 11.99M Avg. Vol.
- 1.69B Shares
- 162.6B Market Cap.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
Motley Fool - Aug 29, 2014
Motley Fool - Aug 26, 2014
Motley Fool - Aug 15, 2014
Gilead wins critical Sovaldi legal fight, Roche finds consolation - MarketWatch (blog)
Motley Fool - Aug 20, 2014
10 S&P 500 companies growing faster than their rivals - MarketWatch
Seeking Alpha (registration) - Aug 26, 2014
Bidness Etc - Aug 18, 2014
Seeking Alpha (registration) - Aug 12, 2014
Gilead Sciences, Inc. (NASDAQ:GILD) Has 19% Upside: Argus - Markets Insider
Seeking Alpha (registration) - Aug 27, 2014
Zacks.com - Aug 29, 2014
Seeking Alpha (registration) - Aug 4, 2014
Hepatitis C cure available — but only if you can afford it - Toronto Star